
|Videos|August 12, 2014
Deciding Between Hormone Therapies in Patients With ER+/PR+ Tumors
Author(s)Ragene Rivera, MD
Ragene Rivera, MD, medical oncologist, Texas Oncology-El Paso Cancer Treatment Center, discusses how she decides between hormone therapies in patients with ER+/PR+ tumors.
Advertisement
Ragene Rivera, MD, medical oncologist, Texas Oncology-El Paso Cancer Treatment Center, discusses how she decides between hormone therapies in patients with ER+/PR+ tumors.
This segment is a part of our Case-Based Peer Perspectives.View the case details > >
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































